<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694355</url>
  </required_header>
  <id_info>
    <org_study_id>sor0089-12-ctil</org_study_id>
    <secondary_id>SCRC12008</secondary_id>
    <nct_id>NCT01694355</nct_id>
  </id_info>
  <brief_title>The Impact of Severe Vitamin D Deficiency and Its Correction on Bone Mineral Density (BMD) in Postmenopausal Women</brief_title>
  <acronym>Vitamin D</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that postmenopausal women are at risk for osteoporosis. The study hypothesis&#xD;
      is that vitamin D deficiency (≤17.5nmol/L) is frequently associated with osteomalacia and&#xD;
      will cause low BMD estimation in DXA scan due to insufficient bone mineralization.&#xD;
&#xD;
      We assume that among these postmenopausal women, Vitamin D treatment will improve bone&#xD;
      mineralization and will cause a rapid increase in BMD. According to the results,&#xD;
      bisphosphonates therapy may be an unnecessary treatment.&#xD;
&#xD;
      The objective of this study is to evaluate the impact of severe vitamin D deficiency and its&#xD;
      correction on Bone Mineral Density (BMD) in postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BMD (Z score) following 10 months of vitamin D supplementation</measure>
    <time_frame>10-14 months</time_frame>
    <description>Will be measured at 3 time points (repeated measures):at baseline visit, after 3-4 months and after 10 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the effect of increasing vitamin D levels on other objective parameters such as PTH, calcium, phosphorus and other subjective parameters such as muscle weakness, according to comparison between baseline visit and end of study visit.</measure>
    <time_frame>10-14 months</time_frame>
    <description>Will be measured at 3 time points (repeated measures):at baseline visit, after 3-4 months and after 10 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent.&#xD;
&#xD;
          2. Female age 55-70&#xD;
&#xD;
          3. At least 2 years past menopause&#xD;
&#xD;
          4. 25(OH)D≤ 17.5nmol/L (≤7 ng/ml)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Vitamin D levels &gt; 30nmol/L in the past 2 years 2. Creatinine &gt; 1.2%mg 3. Calcium ≥&#xD;
        10.2mg/dl 4. Current or previous vitamin D treatment over 2 weeks 5. Previous vitamin D&#xD;
        treatment over 2 months in the past 2 years 6. BMI&gt;35 or BMI&lt;20 7. Menopause before age 45&#xD;
        8. Type 1 diabetes 9. Concomitant disease:&#xD;
&#xD;
          1. Mal-absorptive diseases (Cystic Fibrosis, Crohn's, gastric bypass surgery, celiac&#xD;
             disease)&#xD;
&#xD;
          2. Rheumatoid arthritis&#xD;
&#xD;
          3. Nephrotic syndrome&#xD;
&#xD;
          4. Chronic renal failure&#xD;
&#xD;
          5. Primary hyperparathyroidism&#xD;
&#xD;
          6. Hyperthyroidism&#xD;
&#xD;
          7. Malignancies excluding skin cancers (within the last 5 years)&#xD;
&#xD;
          8. Kidney stones or history of renal colic 10. Medications:&#xD;
&#xD;
          9. Steroids use (past or present)&#xD;
&#xD;
         10. Anti rejection drugs in the last 5 years&#xD;
&#xD;
         11. Anticonvulsant (carbamezapine, hydantoin, Phenobarbital etc) in the last 5 years&#xD;
&#xD;
         12. Any anti osteoporotic medication: Prolia, Bisphosphonates, Teriperatide, Evista,&#xD;
             Protelos, (past or present)&#xD;
&#xD;
         13. Post menopausal HRT (in the last 10 years)&#xD;
&#xD;
         14. Aromatase inhibitors: Femara, Arimadex (past or present)&#xD;
&#xD;
         15. Current use of PPIs (lanton, controloc, zoton, omepradex etc)&#xD;
&#xD;
         16. Current or past use of anti depressant SSRI (favoxil,cipralex etc)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>Merav Fraenkel</investigator_full_name>
    <investigator_title>Senior Endocrinologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

